Evofem Amends Note Agreement, Extends Maturity Date

Evofem Biosciences, Inc. executed a Fourth Amendment to its Securities Purchase Agreement with Adjuvant, modifying the terms of certain convertible promissory notes. The amendment updates the maturity date for these notes to the earlier of six months from April 10, 2026, or a Change of Control at Adjuvant's election. Additionally, the notes cannot be prepaid before six months from the effective date without Adjuvant's written consent.